Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA58723
Max Phase: Preclinical
Molecular Formula: C20H25N5S
Molecular Weight: 367.52
Molecule Type: Small molecule
Associated Items:
ID: ALA58723
Max Phase: Preclinical
Molecular Formula: C20H25N5S
Molecular Weight: 367.52
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1cc(N/C(=N\C(C)C(C)(C)C)Nc2nccs2)c2ccccc2n1
Standard InChI: InChI=1S/C20H25N5S/c1-13-12-17(15-8-6-7-9-16(15)22-13)24-18(23-14(2)20(3,4)5)25-19-21-10-11-26-19/h6-12,14H,1-5H3,(H2,21,22,23,24,25)
Standard InChI Key: APSCGBRBKJTSAJ-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 367.52 | Molecular Weight (Monoisotopic): 367.1831 | AlogP: 5.31 | #Rotatable Bonds: 3 |
Polar Surface Area: 62.20 | Molecular Species: NEUTRAL | HBA: 4 | HBD: 2 |
#RO5 Violations: 1 | HBA (Lipinski): 5 | HBD (Lipinski): 2 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: | CX Basic pKa: 7.66 | CX LogP: 5.03 | CX LogD: 4.58 |
Aromatic Rings: 3 | Heavy Atoms: 26 | QED Weighted: 0.49 | Np Likeness Score: -1.29 |
1. Rachlin S, Bramm E, Ahnfelt-Rønne I, Arrigoni-Martelli E.. (1980) Basic antiinflammatory compounds. N,N',N''-Trisubstituted guanidines., 23 (1): [PMID:6965727] [10.1021/jm00175a004] |
Source(1):